Harmony Biosciences Holdings Inc
Fechado
SetorSaúde
33.78 -0.82
Visão Geral
Variação de preço das ações
24h
Mín
33.32
Máximo
34.26
Rendimento | 10M 32M |
|---|---|
Vendas | -28M 215M |
P/E Médio do Setor | 12.984 49.052 |
EPS | 0.786 |
Margem de lucro | 15.084 |
Funcionários | 293 |
EBITDA | -2.8M 49M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +44.82% upside |
Próximos Ganhos | 4 de ago. de 2026 |
|---|
Capitalização de Mercado | -22M 1.9B |
|---|---|
Abertura anterior | 34.6 |
Fecho anterior | 33.78 |
Sentimento de Notícias
By Acuity
100%
0%
325 / 342 Ranking em Healthcare
Harmony Biosciences Holdings Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
